Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents

医学 斑块性银屑病 安慰剂 银屑病 入射(几何) 皮肤病科 内科学 肽 临床试验 封锁 口服 口腔
作者
Robert Bissonnette,Jennifer Soung,Adelaide Ann Hebert,Andrew Pink,Andreas Pinter,Angela Yen Moore,Yuling Shi,Wenhui Wang,Darryl P. Toth,Megan Miller-Kassamali,Joseph Cafone,Jingzhi Jiang,Shu Li,Cynthia Marie Carver DeKlotz,Fabio P. Nunes,Mark Lebwohl
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:393 (18): 1784-1795 被引量:52
标识
DOI:10.1056/nejmoa2504187
摘要

BACKGROUND: Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving adults and adolescents (≥12 years of age) with moderate-to-severe plaque psoriasis, as defined by all the following: a total body-surface area of psoriasis involvement of at least 10%, a Psoriasis Area and Severity Index (PASI) score of at least 12 (range, 0 to 72, with higher scores indicating a greater extent or severity of psoriasis), and an Investigator's Global Assessment (IGA) score of at least 3 (range, 0 [clear skin] to 4 [severe disease]). Participants were assigned in a 2:1 ratio to receive icotrokinra at a dose of 200 mg once daily through week 24 or placebo through week 16 followed by transition to icotrokinra. The coprimary end points were an IGA 0/1 response (IGA score of 0 or 1 with ≥2-point reduction from baseline) and a PASI 90 response (≥90% reduction from baseline in the PASI score) at week 16. RESULTS: A total of 684 participants underwent randomization (456 to the icotrokinra group and 228 to the placebo group). At week 16, a total of 65% of the participants receiving icotrokinra and 8% of those receiving placebo had an IGA 0/1 response, and 50% and 4%, respectively, had a PASI 90 response (P<0.001 for both comparisons). Complete clearance of skin at week 16 was significantly more likely with icotrokinra than with placebo (IGA score of 0, 33% vs. 1%; PASI 100 response [100% reduction from baseline in the PASI score], 27% vs. <1%; P<0.001 for both comparisons). The percentage of participants with at least one adverse event through week 16 was 49% in each group; the most common adverse events in each group were nasopharyngitis and upper respiratory tract infection. The exposure-adjusted incidence of adverse events was consistent through week 24. CONCLUSIONS: : Targeted Oral Peptide Icotrokinra for Psoriasis Involving High‑Impact Sites.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Juvenilesy的应助被科研通管家采纳,获得10
刚刚
Lucas的应助被科研通管家采纳,获得10
刚刚
刚刚
SciGPT的应助被科研通管家采纳,获得10
刚刚
刚刚
刚刚
fantasy的应助被科研通管家采纳,获得10
刚刚
赘婿的应助被科研通管家采纳,获得10
刚刚
香蕉觅云的应助被涵霸天采纳,获得10
刚刚
刚刚
DOC_XIONG的应助被科研通管家采纳,获得10
刚刚
Ava的应助被科研通管家采纳,获得10
1秒前
佳佳发布了新的文献求助10
1秒前
香蕉觅云的应助被科研通管家采纳,获得10
1秒前
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
今后的应助被科研通管家采纳,获得10
1秒前
CodeCraft的应助被科研通管家采纳,获得10
1秒前
李爱国的应助被科研通管家采纳,获得10
1秒前
bkagyin的应助被lu采纳,获得10
2秒前
沉默星星发布了新的文献求助10
2秒前
3秒前
汉堡包的应助被哈哈采纳,获得10
3秒前
Muhebbet发布了新的文献求助100
3秒前
彭于晏的应助被虚幻百招采纳,获得10
3秒前
丘比特的应助被虚幻百招采纳,获得10
3秒前
fantasy的应助被虚幻百招采纳,获得10
4秒前
rosa完成签到,获得积分10
4秒前
fantasy的应助被虚幻百招采纳,获得10
4秒前
搜集达人的应助被虚幻百招采纳,获得10
4秒前
小蘑菇的应助被虚幻百招采纳,获得10
4秒前
烟花的应助被虚幻百招采纳,获得10
4秒前
zhs完成签到,获得积分10
4秒前
酷波er的应助被虚幻百招采纳,获得10
5秒前
我是老大的应助被虚幻百招采纳,获得10
5秒前
在水一方的应助被虚幻百招采纳,获得10
5秒前
lin发布了新的文献求助10
5秒前
星辰大海的应助被ju00采纳,获得10
5秒前
开冲完成签到,获得积分10
5秒前
RNNNLL完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175336
求助须知:如何正确求助?哪些是违规求助? 9567158
关于积分的说明 21790491
捐赠科研通 7769866
什么是DOI,文献DOI怎么找? 3431849
关于科研通互助平台的介绍 2556178
邀请新用户注册赠送积分活动 2477280